Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog
- 1 January 1992
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 22 (11) , 1339-1351
- https://doi.org/10.3109/00498259209053162
Abstract
1. Single oral doses of 14C-5-methoxypsoralen (5-MOP) to human subjects (50 mg), rats (1 mg/kg) and dogs (1 mg/kg) were fairly well absorbed but subjected to extensive first-pass metabolism, at least in rat and human. Means of 62, 51 and 40% dose in urine and 31, 38 and 48% dose in faeces, were excreted by humans (during 5 days), rats (3 days) and dogs (1 day), respectively. In dogs, faecal 14C was probably derived, in part, from biliary excreted material. 2. Total 14C in human plasma reached peak concentrations after 2 h (mean 235 ng 5-MOP equivalent/ml) and declined relatively slowly, to about 60% of this value within 24 h. Unchanged 5-MOP was not detected in plasma using h.p.l.c. (< 5 ng/ml). 3. Tissue concentrations of 14C were generally greater in dogs than rats and reached peak levels at 1 h in dogs but at 24 h in rats. Apart from liver and bile, dog tissue 14C concentrations were lower than those in the corresponding plasma, whereas in rat they were lower only until the time of peak concentrations, after which they were generally greater. 4. 5-MOP was extensively metabolized in all three species. The major 14C-components in human and dog urine were glucuronic acid conjugates, mainly of an arylacetic acid and arylalcohols, resulting from initial oxidative metabolism of the furan ring of 5-MOP. In rat, these metabolites were excreted mainly unconjugated. An unusual metabolite was formed by reduction of the lactone moiety of 5-MOP, probably by the gut flora, giving rise to an arylpropionic acid, excreted as a glucuronic acid conjugate in the urine of all three species. 5. Unchanged drug was a very minor component of human and rat plasma, but a major component of dog plasma. In all three species, circulating 14C-metabolites were similar to those in the urine but were present mainly unconjugated. On the basis of these data, the metabolic fate of 5-MOP in humans was more similar to that in dog than to that in rat, although humans appeared to metabolize 5-MOP more rapidly than did dog.Keywords
This publication has 11 references indexed in Scilit:
- Clinical Pharmacokinetics of Methoxsalen and Other PsoralensClinical Pharmacokinetics, 1986
- Dosage du méthoxy-5 psoralène dans le plasma par chromatographie en phase liquide et detection spectrofluorimétriqueJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- Serum and urine concentrations of 5-methoxypsoralen after oral administrationBritish Journal of Dermatology, 1981
- The metabolism of 8-methoxypsoralen in manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1980
- The distribution, excretion and biotransformation ofp-dichloro[14C]benzene in rats after repeated inhalation, oral and subcutaneous dosesXenobiotica, 1980
- 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasisBritish Journal of Dermatology, 1979
- Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dogArchives of Dermatological Research, 1978
- Molecular and genetic basis of furocoumarin reactionsMutation Research/Reviews in Genetic Toxicology, 1976
- The Metabolic Fate of the Coronary Dilator 4-(3,4,5-Trimethoxycinnamoyl)-1-(N-Isopropylcarbamoylmethyl)- Piperazine in the Rat, Dog and ManXenobiotica, 1974
- Studies on the Role of the Intestinal Microflora in the Metabolism of Coumarin in RatsActa Pharmacologica et Toxicologica, 1968